Topic

Found 728,010 articles

• MCRA Assists Noctrix Health with FDA Marketing Authorization via the De Novo Pathway for the NTX100 Tonic Motor Activation System

  5/8/2023

  MCRA, LLC is pleased to announce its role in assisting Noctrix Health obtain marketing authorization via a De Novo Request from the U.S. Food and Drug Administration (FDA) for the NTX100 Tonic Motor Activation (NTX100 TOMAC) System.

• Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance

  5/8/2023

  Catalent, Inc. today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023.

• Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

  5/8/2023

  Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’s oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

• Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's Plan

  5/8/2023

  Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength of its Board and noting that Carl Icahn's "plan" for Illumina is sloppy and uninformed.

• Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.”

• Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

  5/8/2023

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.

• Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

  5/8/2023

  Akebia to host conference call on May 8 at 8:30 a.m. ET.

• Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

  5/8/2023

  Insmed Incorporated today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the Company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

• Codexis Announces New Employment Inducement Grants - May 08, 2023

  5/8/2023

  Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors.

• ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

  5/8/2023

  Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023.

• Quest HealthConnect(TM): Personalized Access to Quality Healthcare

  5/8/2023

  Enabled by a national network of trusted, long-standing relationships with medical professionals, Quest HealthConnect provides a personalized approach, often at members' homes, through an on-site Health Risk Assessment.

• ICU Medical Announces First Quarter 2023 Results

  5/8/2023

  ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products, announced financial results for the quarter ended March 31, 2023.

• 4D Molecular Therapeutics to Participate in Upcoming May 2023 Investor Conferences

  5/8/2023

  4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced it will participate in the following upcoming investor conferences.

• Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

  5/8/2023

  Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week ® 2023.

• Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion

  5/8/2023

  Baxter International Inc., a leading global medtech company, announced that it has signed a definitive agreement to divest its BioPharma Solutions business to Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor.

• Cytokinetics to Participate in the JMP Securities Life Sciences Conference

  5/8/2023

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY.

• Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

  5/8/2023

  Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.

• Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

  5/8/2023

  Citius Pharmaceuticals Inc. announced the closing of its previously announced registered direct offering with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,500,001 shares of its common stock, at a purchase price of $1.20 per share and accompanying warrant.

• Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

  5/8/2023

  Acasti Pharma Inc. today announced the successful submission to the FDA of GTX-104's full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.

• TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028

  5/8/2023

  TransMedics Group, Inc. today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes.